Pfizer oral COVID-19 pill gets U.S. authorisation

Posted on Dec 22, 2021

The US Food and Drug Administration on Wednesday authorized Pfizer's antiviral pill, Paxlovid, to treat Covid-19. This is the first antiviral Covid-19 pill authorized for ill people to take at home, before they get sick enough to be hospitalized.

Following FDA emergency use authorisation today EMA endorsement is anticipated early 2022

In the U.S. alone Paxlovid could prevent over half a million deaths and hospitalisations (with respect to the treatment of the high-risk population) in 2022

Today the U.K. confirmed a supply deal for an additional 2.5 million doses of Paxlovid

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022